ERBB2 and breast cancer: No RB1 or ESR1 alterations were detected, which are typically associated with reduced efficacy of CDK4/6 inhibitors in the metastatic setting or with acquired resistance to endocrine therapy in HR+/HER2-BC (Table 1).